The International Diabetes Federation confirms type 5 diabetes caused by malnutrition, affecting millions of young people living in poverty.

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same ...

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...

It differs from a regular ultrasound, which can also reveal early signs of a fatty liver, because it can quantify how much ...

There isn't a one-size-fits-all treatment for perimenopause symptoms, but you can start by tackling your most bothersome ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

I did a recent health test. Usually, my colleagues who were tasked to be our company champions would help arrange a company ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

The FDA has accepted the New Drug Application for ET-600, an oral solution formulation of desmopressin, for the treatment of central diabetes insipidus.

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with ...